Genitourinary Cancers

Juan A. Reyna, MD, President, LUGPA, discusses in-office ancillary services among LUGPA members.

Raoul Concepcion, MD, director of clinical research, urologic surgeon, Urology Associates, PC, in Nashville, Tennessee discusses some of the challenges that independent and community urologists face.

The mTOR inhibitor temsirolimus has limited utility in combination with frontline bevacizumab and as a second-line single agent for patients with metastatic renal cell carcinoma

Hyponatremia is significantly associated with worse outcomes in patients with metastatic renal cell carcinoma (mRCC) who received treatment with VEGF- and mTOR-targeted agents

Matthew D. Galsky, MD, assistant professor of medicine, Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, discusses the role of ipilimumab in bladder cancer.

With seven targeted therapies approved for metastatic renal cell carcinoma, researchers and drug developers are now focusing on understanding the best way to sequence these therapies and on identifying predictive biomarkers of response.

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses sequencing nivolumab in the treatment of renal cell carcinoma.

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the potential of immunotherapy agents as treatment for bladder cancer.

Over the past few years, seven new drugs have gained approval from the FDA for the treatment of patients with metastatic renal cell carcinoma. Primarily these approaches target angiogenesis and mTOR. The advent of these molecularly targeted therapies has significantly improved the standard of care for patients with RCC.

Matthew D. Galsky, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, explains the mechanism of action of ipilimumab in bladder cancer.

Urologists who treat men with prostate cancer are 2.5 times more likely to refer patients to intensity-modulated radiation therapy centers, especially if they have a financial stake in the IMRT center.

The investigational autologous dendritic cell vaccine AGS-003 successfully activated a cytotoxic T cell response that correlates with a prolongation in survival for patients with metastatic renal cell carcinoma

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy of renal cell carcinoma (RCC).

Everolimus provides clinical benefit to patients with papillary metastatic renal cell carcinoma, offering promising overall survival results and a tolerable side-effect profile, investigators found in a study presented during the 2013 European Cancer Congress in Amsterdam.

We as physicians, especially surgeons, tend to operate on the same principle: When things go bad, especially when revenue goes down, we just work harder and see more patients, with the expectation that it will correct and we can maintain.

Manuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted therapies in renal cell carcinoma (RCC).

An international research team led by scientists from Georgetown Lombardi Comprehensive Cancer Center has discovered a genetic mutation linked to low-risk bladder cancer.

Viktor Grünwald, MD, PhD, an attending physician at the Hannover Medical School, discusses tumor remission in patients with renal cell carcinoma (RCC).

Daniel J. George, MD, director, GU Oncology, Duke Cancer Institute, discusses the use of sunitinib to treat patients with renal cell carcinoma (RCC).

The American Cancer Society estimates that in 2013, 142,820 individuals in the United States will be diagnosed with colorectal cancer and 72,570 with bladder cancer

USO co-founders John Forrest, MD, and Robert Bruce, MD, have known each other since the fourth grade. They both attended medical school at the University of Oklahoma and, after some time away from home, ultimately joined two different, well-established practices in north and south Tulsa.

Dovitinib failed to meet the primary endpoint of improving progression-free survival versus sorafenib (Nexavar) in patients with heavily pretreated progressive renal cell carcinoma

Manuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted agents in renal cell cancer, including hypertension, diarrhea, and hand-foot syndrome.

Viktor Grünwald, MD, PhD, from the Hannover Medical School, discusses a phase III trial that compared dovitinib to sorafenib for patients with mRCC following prior treatment with one VEGF inhibitor and one mTOR inhibitor.

Daniel J. George, MD, Director, GU Oncology, Duke Cancer Institute, discusses critical phase III clinical trials in metastatic renal cell carcinoma.